WAVELENGTH‐DEPENDENT EFFECTS OF BENZOPORPHYRIN DERIVATIVE MONOACID RING A in vivo AND in vitro

Abstract

Benzoporphyrin derivative monoacid ring A (BPD-MA) is a chlorin-like photosensitizer currently in clinical trials for cancer and psoriasis. It has maximal absorption peaks at both 630 and 690 nm and can be activated at both these wavelengths. In vitro phototoxicity tests using the P815 murine mastocytoma cell lines conducted over wavelengths of light between 678 and 700 nm emitted by an argon-ion pumped dye laser showed that equivalent cell kill could be achieved between 682 and 690 nm. Tests on in vivo phototoxicity of normal skin of DBA/2 mice injected with 2 mg/kg of BPD-MA and exposed to light at 125 J/cm2, between 620 and 700 nm, demonstrated peaks of normal skin damage occurring at 630-640 nm and 680-690 nm. In tests carried out with light between 620 and 700 nm, at 10 nm increments, it was seen that light delivered at 680-690 nm caused slightly more damage to normal skin than light delivered at 630-640 nm. When lower doses of light between 675 and 705 nm were tested using smaller increments, it was determined that equivalent skin damage occurred over a range of 680-695 nm. Antitumor efficacy in tumor-bearing DBA/2 mice was tested between 683 and 695 nm. It was found that equivalent antitumor efficacy, determined by assessing tumor-free status at 20 days posttreatment, occurred at wavelengths between 685 and 693 nm.(ABSTRACT TRUNCATED AT 250 WORDS)

Photodynamic therapy using Verteporfin (benzoporphyrin derivative monoacid ring A, BPD‐MA) and 630 nm laser light in canine esophagus*

“…Vertepor®n is typically activated at its optimum absorption peak of 690 nm which is approximately four times that of it absorption at 630 nm [11]. It would then be expected that the required 630 nm light dose would be increased by the same factor.…”

“…However, it can also be activated at 630 nm [11]. In the case of Barrett's esophagus and early cancers of the esophagus, activation at the wavelength of 630 nm is desirable since deeper penetration of 690 nm in tissue is not necessary.…”

Photodynamic therapy with 9-hydroxypheophorbide α on AMC-HN-3 human head and neck cancer cells: Induction of apoptosis via photoactivation of mitochondria and endoplasmic reticulum

“…AMC-HN-3 cells were loaded with rhodamine 123 to monitor MMP in single cell precursor and verteporfin as a benzoporphyrin derivative have been developed as the next generation of photosensitizers. 9,10 A pheophorbide-derived photosensitizer was also developed for PDT to overcome skin photosensitivity. 11,12 In the current study, a novel pheophorbide-based photosensitizer, 9-hydroxypheophorbide α (9-HPbD), 13 was used to assess the photocytoxicity to AMC-HN-3 cancer cells.…”

Enhanced apoptotic effect of combined modality of 9-hydroxypheophorbide α-mediated photodynamic therapy and carboplatin on AMC-HN-3 human head and neck cancer cells

“…Most of the photosensitizers used are effective, but showed skin phototoxicity (8,9). Previously, new photosensitizers were developed for PDT to overcome shin phototoxicity (18,(20)(21)(22)(23), 9-HPbD, a novel pheophorbide-based photosensitizer as a chlorophyll derivative, was used in this study for PDT on AMC-HN-3 cells to investigate whether or not the increased cytotoxicity and the enhanced apoptosis can be obtained through combining with CBDCA. The combination treatment was expected to and GAPDH (E) in AMC-HN-3 head and neck cancer cells at 0, 3, 6 and 12 h after PDT combined with CBDCA or not.…”